CY1125016T1 - Διαμορφωτες υποδοχεα πιπεριδινης cxcr7 - Google Patents
Διαμορφωτες υποδοχεα πιπεριδινης cxcr7Info
- Publication number
- CY1125016T1 CY1125016T1 CY20221100143T CY221100143T CY1125016T1 CY 1125016 T1 CY1125016 T1 CY 1125016T1 CY 20221100143 T CY20221100143 T CY 20221100143T CY 221100143 T CY221100143 T CY 221100143T CY 1125016 T1 CY1125016 T1 CY 1125016T1
- Authority
- CY
- Cyprus
- Prior art keywords
- receptor modulators
- cxcr7
- piperidine
- chemical formula
- rar1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Abstract
Η παρούσα εφεύρεση σχετίζεται με παράγωγα πιπεριδίνης του χημικού τύπου Ι όπου τα Ar1, Ar2, RAr1, R1, R2, και R3 είναι όπως περιγράφονται στην Περιγραφή, με την παρασκευή τους, με φαρμακευτικά αποδεκτά άλατα τους, και με τη χρήση τους ως φαρμακευτικές ουσίες, με φαρμακευτικές συνθέσεις που περιέχουν μια ή περισσότερες ενώσεις του Χημικού τύπου (Ι), και ιδίως με τη χρήση τους ως διαμορφωτές υποδοχέα CXCR7.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2016068052 | 2016-07-28 | ||
PCT/EP2017/068990 WO2018019929A1 (en) | 2016-07-28 | 2017-07-27 | Piperidine cxcr7 receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1125016T1 true CY1125016T1 (el) | 2023-03-24 |
Family
ID=59656027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20221100143T CY1125016T1 (el) | 2016-07-28 | 2022-02-21 | Διαμορφωτες υποδοχεα πιπεριδινης cxcr7 |
Country Status (32)
Country | Link |
---|---|
US (2) | US10752620B2 (el) |
EP (2) | EP3490986B1 (el) |
JP (2) | JP6655754B2 (el) |
KR (2) | KR102497091B1 (el) |
CN (2) | CN109563085B (el) |
AR (2) | AR109180A1 (el) |
AU (2) | AU2017302079B2 (el) |
BR (1) | BR112019001551A2 (el) |
CA (1) | CA3032017C (el) |
CL (2) | CL2019000169A1 (el) |
CY (1) | CY1125016T1 (el) |
DK (2) | DK3490986T3 (el) |
EA (2) | EA037507B1 (el) |
ES (2) | ES2905755T3 (el) |
FI (1) | FI3798217T3 (el) |
HR (2) | HRP20211988T1 (el) |
HU (2) | HUE062019T2 (el) |
IL (2) | IL264424B (el) |
LT (2) | LT3490986T (el) |
MA (2) | MA54653B1 (el) |
MX (2) | MX2019001042A (el) |
MY (1) | MY198113A (el) |
NZ (1) | NZ751006A (el) |
PH (1) | PH12019500188A1 (el) |
PL (2) | PL3490986T3 (el) |
PT (2) | PT3490986T (el) |
RS (2) | RS64130B1 (el) |
SG (2) | SG10201906942PA (el) |
SI (2) | SI3798217T1 (el) |
TW (3) | TWI691494B (el) |
WO (1) | WO2018019929A1 (el) |
ZA (1) | ZA201901256B (el) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020015024A2 (pt) * | 2018-01-26 | 2021-01-19 | Idorsia Pharmaceuticals Ltd | Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método de profilaxia ou tratamento de câncer, distúrbios autoimunes, doenças inflamatórias, rejeição a transplante ou fibrose |
TW202131921A (zh) | 2019-10-31 | 2021-09-01 | 瑞士商愛杜西亞製藥有限公司 | Cxcr7拮抗劑與s1p1受體調節劑之組合 |
CA3226468A1 (en) | 2021-08-02 | 2023-02-09 | Andrew Edmunds | Microbiocidal pyrazole derivatives |
EP4353720A1 (en) * | 2021-10-01 | 2024-04-17 | Nextgen Bioscience Co., Ltd. | Novel piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same |
WO2023110871A1 (en) | 2021-12-17 | 2023-06-22 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
EP4238970A1 (en) * | 2022-03-03 | 2023-09-06 | InterAx Biotech AG | Modulators of ackr3 and uses thereof |
CN115403510B (zh) * | 2022-08-11 | 2023-04-25 | 南方医科大学 | 一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040102324A1 (en) * | 2002-02-28 | 2004-05-27 | Annis Gary David | Heterocyclic diamide invertebrate pest control agents |
CA2507501C (en) | 2002-11-27 | 2011-10-04 | Incyte Corporation | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
TW200526626A (en) * | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
US7115646B2 (en) | 2003-10-08 | 2006-10-03 | Bristol Myers Squibb, Co. | Cyclic diamines and derivatives as factor Xa inhibitors |
KR20070113233A (ko) | 2005-02-18 | 2007-11-28 | 아스트라제네카 아베 | 항균성 피페리딘 유도체 |
MX2011004490A (es) * | 2008-11-04 | 2011-07-20 | Chemocentryx Inc | Moduladores de cxcr7. |
WO2012168315A1 (en) | 2011-06-09 | 2012-12-13 | Boehringer Ingelheim International Gmbh | Substituted piperidines as gpr119 modulators for the treatment of metabolic disorders |
WO2013084241A1 (en) * | 2011-12-09 | 2013-06-13 | Cadila Healthcare Limited | Compounds as inhibitors of renin |
AR091516A1 (es) | 2012-06-22 | 2015-02-11 | Actelion Pharmaceuticals Ltd | Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida |
KR102196374B1 (ko) * | 2012-11-29 | 2020-12-31 | 케모센트릭스, 인크. | Cxcr7 길항제 |
MY173564A (en) | 2013-05-30 | 2020-02-04 | Idorsia Pharmaceuticals Ltd | Cxcr7 receptor modulators |
CN105705489B (zh) | 2013-09-04 | 2019-04-26 | 百时美施贵宝公司 | 用作免疫调节剂的化合物 |
AU2014316682B2 (en) | 2013-09-06 | 2018-11-22 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole derivatives as immunomodulators |
WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
WO2016040515A1 (en) * | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Substituted piperidine compounds |
WO2016087370A1 (en) * | 2014-12-01 | 2016-06-09 | Actelion Pharmaceuticals Ltd | Cxcr7 receptor modulators |
BR112020015024A2 (pt) | 2018-01-26 | 2021-01-19 | Idorsia Pharmaceuticals Ltd | Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método de profilaxia ou tratamento de câncer, distúrbios autoimunes, doenças inflamatórias, rejeição a transplante ou fibrose |
-
2017
- 2017-07-27 RS RS20230297A patent/RS64130B1/sr unknown
- 2017-07-27 KR KR1020197005980A patent/KR102497091B1/ko active IP Right Grant
- 2017-07-27 SI SI201731333T patent/SI3798217T1/sl unknown
- 2017-07-27 PL PL17754283T patent/PL3490986T3/pl unknown
- 2017-07-27 JP JP2019503918A patent/JP6655754B2/ja active Active
- 2017-07-27 EP EP17754283.4A patent/EP3490986B1/en active Active
- 2017-07-27 MY MYPI2019000420A patent/MY198113A/en unknown
- 2017-07-27 TW TW108111236A patent/TWI691494B/zh active
- 2017-07-27 TW TW108111240A patent/TWI691497B/zh active
- 2017-07-27 BR BR112019001551-5A patent/BR112019001551A2/pt active Search and Examination
- 2017-07-27 WO PCT/EP2017/068990 patent/WO2018019929A1/en active Application Filing
- 2017-07-27 EA EA201990388A patent/EA037507B1/ru not_active IP Right Cessation
- 2017-07-27 MA MA54653A patent/MA54653B1/fr unknown
- 2017-07-27 SG SG10201906942PA patent/SG10201906942PA/en unknown
- 2017-07-27 CA CA3032017A patent/CA3032017C/en active Active
- 2017-07-27 HR HRP20211988TT patent/HRP20211988T1/hr unknown
- 2017-07-27 EA EA202091262A patent/EA202091262A1/ru unknown
- 2017-07-27 ES ES17754283T patent/ES2905755T3/es active Active
- 2017-07-27 HU HUE20201796A patent/HUE062019T2/hu unknown
- 2017-07-27 SI SI201731053T patent/SI3490986T1/sl unknown
- 2017-07-27 US US16/320,906 patent/US10752620B2/en active Active
- 2017-07-27 RS RS20220082A patent/RS62855B1/sr unknown
- 2017-07-27 HR HRP20230313TT patent/HRP20230313T1/hr unknown
- 2017-07-27 DK DK17754283.4T patent/DK3490986T3/da active
- 2017-07-27 NZ NZ751006A patent/NZ751006A/en unknown
- 2017-07-27 AU AU2017302079A patent/AU2017302079B2/en active Active
- 2017-07-27 LT LTEPPCT/EP2017/068990T patent/LT3490986T/lt unknown
- 2017-07-27 LT LTEP20201796.8T patent/LT3798217T/lt unknown
- 2017-07-27 MX MX2019001042A patent/MX2019001042A/es unknown
- 2017-07-27 PT PT177542834T patent/PT3490986T/pt unknown
- 2017-07-27 SG SG11201900633XA patent/SG11201900633XA/en unknown
- 2017-07-27 EP EP20201796.8A patent/EP3798217B1/en active Active
- 2017-07-27 CN CN201780046279.9A patent/CN109563085B/zh active Active
- 2017-07-27 ES ES20201796T patent/ES2954152T3/es active Active
- 2017-07-27 DK DK20201796.8T patent/DK3798217T3/da active
- 2017-07-27 PL PL20201796.8T patent/PL3798217T3/pl unknown
- 2017-07-27 CN CN201910748606.6A patent/CN110563717B/zh active Active
- 2017-07-27 HU HUE17754283A patent/HUE057315T2/hu unknown
- 2017-07-27 MA MA45782A patent/MA45782B1/fr unknown
- 2017-07-27 FI FIEP20201796.8T patent/FI3798217T3/fi active
- 2017-07-27 PT PT202017968T patent/PT3798217T/pt unknown
- 2017-07-27 TW TW106125273A patent/TWI683812B/zh active
- 2017-07-27 AR ARP170102126A patent/AR109180A1/es unknown
- 2017-07-27 KR KR1020207021496A patent/KR102497095B1/ko active IP Right Grant
-
2019
- 2019-01-22 CL CL2019000169A patent/CL2019000169A1/es unknown
- 2019-01-23 IL IL264424A patent/IL264424B/en unknown
- 2019-01-24 MX MX2021004000A patent/MX2021004000A/es unknown
- 2019-01-25 PH PH12019500188A patent/PH12019500188A1/en unknown
- 2019-02-27 ZA ZA2019/01256A patent/ZA201901256B/en unknown
- 2019-03-15 JP JP2019048980A patent/JP6655742B2/ja active Active
- 2019-07-01 AR ARP190101842A patent/AR115662A2/es unknown
- 2019-11-15 CL CL2019003281A patent/CL2019003281A1/es unknown
-
2020
- 2020-07-09 AU AU2020204578A patent/AU2020204578B2/en active Active
- 2020-07-14 US US16/928,787 patent/US11306078B2/en active Active
-
2021
- 2021-05-05 IL IL282942A patent/IL282942B/en unknown
-
2022
- 2022-02-21 CY CY20221100143T patent/CY1125016T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1125016T1 (el) | Διαμορφωτες υποδοχεα πιπεριδινης cxcr7 | |
CY1118735T1 (el) | Παραγωγα βενζιμιδαζολο-προλινης | |
CY1122870T1 (el) | Νεα πιπεριδινυλ παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που τα περιεχουν | |
CY1123645T1 (el) | Δικυκλικα παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα | |
CY1122560T1 (el) | Νεα παραγωγα αμμωνιου, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουναυτα | |
CY1123069T1 (el) | Νεα (ετερο)αρυλ-υποκατεστημενα-πιπεριδινυλ παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα | |
CY1117638T1 (el) | Παραγωγα του 2-(1,2,3-τριαζολ-2-υλο)βενζαμιδιου και του 3-(1,2,3-τριαζολ-2-υλο)πικολιναμιδιου ως ανταγωνιστες του υποδοχεα της ορεξινης | |
CY1124726T1 (el) | Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv | |
CY1122065T1 (el) | Ενωσεις αλκυλ-αμιδο-υποκατεστημενου πυριδυλιου χρησιμες ως διαμορφωτες των αποκρισεων il-12, il-23 και/η ιfναλφα | |
CY1123407T1 (el) | Σταθερες υδατικες φαρμακοτεχνικες μορφες της αδαλιμουμαμπης | |
CY1121804T1 (el) | Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους | |
CY1124620T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
CY1124496T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
CY1124222T1 (el) | Ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με μεθυλο/φθορο-πυριδινυλο-μεθοξυ και ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με φθορο-πυριδινυλο-μεθοξυ | |
CY1124913T1 (el) | Ν-υποκατεστημενα παραγωγα ινδολης ως διαμορφωτες υποδοχεα pge2 | |
CY1116150T1 (el) | Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842 | |
CY1119387T1 (el) | Τριαζολοπυραζινες ως αναστολεις brd4 για χρηση στην αντιμετωπιση καρκινου | |
CY1119953T1 (el) | Yποκατεστημενες πυριδοπυραζινες ως προτυποι syk ανοστολεις | |
CY1119619T1 (el) | Παραγωγα πυριδιν-4-υλιου | |
MD3313849T2 (ro) | Noi derivați de hidroxiacid, procedeu de preparare a acestora și compoziții farmaceutice care îi conțin | |
CY1110419T1 (el) | Τρικυκλικες ενωσεις με βαση το 1,6-διυδρο-1,3,5,6-tetpaaza-as-ινδακενιο και φαρμακευτικες συνθεσεις που τις περιεχουν ως αναστολεις της ενζυμικης ενεργοτητας της ικκ | |
CY1121326T1 (el) | Υποκατεστημενη 2,4 διαμινο-κινολινη ως νεοι αντικαρκινικοι παραγοντες | |
CY1123349T1 (el) | Ενωσεις 6-ετεροκυκλυλ-4-μορφολιν-4-υλπυρiδιν-2-οnhς χρησιμες για τη θεραπεια καρκινου και διαβητη |